Angus Liu is a Senior Staff Writer for Fierce Pharma, specializing in biopharma news and developments. With a background in journalism from Medill School of Journalism, Angus covers topics such as regulatory updates, drug launches, clinical trials, and industry trends. His work has been featured in Fierce Biotech as well, showcasing his expertise in the biotechnology sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Angus Liu's coverage predominantly focuses on the healthcare and pharmaceutical industry. His articles reflect a strong emphasis on drug development, FDA approvals, clinical trials, and specific medications within the pharmaceutical industry.
Given this focus, Angus would likely be receptive to pitches from experts who have in-depth knowledge of drug development processes or regulatory affairs in the pharmaceutical industry. Pitches offering insights into recent clinical trial outcomes or FDA announcements related to new drugs may also capture his interest.
Sources with access to relevant data or those involved in government announcements pertaining to healthcare regulation could also provide valuable perspectives for Angus's coverage. It is important for potential sources to offer fact-based analysis and credible commentary that aligns with the themes covered in Angus's articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angus Liu
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and improper collection of patient data. Pfizer plans to invest $1 billion in China in the next five years. Sun Pharma's JAK inhibitor Leqselvi was slapped with an injunction in a lawsuit with Incyte. And more.
By: Angus Liu
After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood diso
By: Angus Liu
Despite China's investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper collection of patient data that have implicated senior executives, AstraZeneca CEO Pascal Soriot argued that the company did not lose oversight.
By: Angus Liu
After a series of acquisitions and an activist investor's accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit,
By: Angus Liu
While personally “disappointed” about the election's outcome, current FDA Commissioner Robert Califf, M.D., has laid out the qualities that he hopes his successor will have.
By: Angus Liu
GSK's £3 billion peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win.
By: Angus Liu
Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen's Alzheimer's disease drug Leqembi.
By: Angus Liu
Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued that the company did not lose compliance oversight in China amid local authorities' investigations into the drugmaker's senior executives. AZ and Daiichi Sankyo have refiled their TROP2 antibody-drug conjugate with the FDA. And more.
By: Angus Liu
In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutting down its U.S.
By: Angus Liu
A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo's star antibody-drug conjugate Enhertu.
(833) 317-6278 
